Utah Code 26B-3-137. Reimbursement for diabetes prevention program

26B-3-137. Reimbursement for diabetes prevention program.

(1)	As used in this section, “DPP” means the National Diabetes Prevention Program developed by the United States Centers for Disease Control and Prevention.

Amendment: A proposal to alter the text of a pending bill or other measure by striking out some of it, by inserting new language, or both. Before an amendment becomes part of the measure, thelegislature must agree to it.
Appropriation: The provision of funds, through an annual appropriations act or a permanent law, for federal agencies to make payments out of the Treasury for specified purposes. The formal federal spending process consists of two sequential steps: authorization
Medicaid program: means the state program for medical assistance for persons who are eligible under the state plan adopted pursuant to Title XIX of the federal Social Security Act. See Utah Code 26B-3-101
State: when applied to the different parts of the United States, includes a state, district, or territory of the United States. See Utah Code 68-3-12.5
United States: includes each state, district, and territory of the United States of America. See Utah Code 68-3-12.5

(2)

Beginning July 1, 2022, the Medicaid program shall reimburse a provider for an enrollee’s participation in the DPP if the enrollee:

(a)	meets the DPP’s eligibility requirements; and

(b)	has not previously participated in the DPP after July 1, 2022, while enrolled in the Medicaid program.

(3)	Subject to appropriation, the Medicaid program may set the rate for reimbursement.

(4)	The department may apply for a state plan amendment if necessary to implement this section.

(5)

(a)	On or after July 1, 2025, but before October 1, 2025, the department shall provide a written report regarding the efficacy of the DPP and reimbursement under this section to the Health and Human Services Interim Committee.

(b)

The report described in Subsection (5)(a) shall include:

(i)	the total number of enrollees with a prediabetic condition as of July 1, 2022;

(ii)	the total number of enrollees as of July 1, 2022, with a diagnosis of type 2 diabetes;

(iii)

the total number of enrollees who participated in the DPP;

(iv)	the total cost incurred by the state to implement this section; and

(v)	any conclusions that can be drawn regarding the impact of the DPP on the rate of type 2 diabetes for enrollees.

Renumbered and Amended by Chapter 306, 2023 General Session